Mayo Foundation for Medical Education and Research

W. L. Gore & Associates, Inc.

Allan B Dietz

Michael P Gustafson

Sanjay Misra

Peggy A Bulur

Greg W Butler

Gaylord Knutson

Benjamin I Espen

William A Faubion

Eric J Dozois

Reed A Houge

Yi Lin

Brendan S Buchanan

Platelet lysate compositions and cell culture media compositions for maintaining and/or growing mammalian cells, such as mammalian endothelial cells (ECs) and mammalian endothelial progenitor cells (EPCs), in particular human ECs (huECs) and human EPCs (huEPCs), such as primary huECs and primary huEPCs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors. Also provided are methods for making and using such cell culture media compositions to grow and/or maintain ECs and EPCs, including huECs and huEPCs, as well as cell culture vessels, dishes, plates, and/or flasks pretreated with the cell culture media compositions.

Cell culture media compositions for primary cells

This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided.

Compositions containing platelet contents

This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4lymphocytes, CD8lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14HLA-DRmonocytes, and/or CD86monocytes per unit volume (e.g., cells per μL or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

Methods and materials for assessing immune system profiles

This document provides methods and materials involved in reducing venous neointimal hyperplasia (VNH) of an arteriovenous fistula (AVF) or graft. For example, methods and materials for using stem cells (e.g., mesenchymal stem cells), extracellular matrix material, or a combination of stem cells and extracellular matrix material to reduce VNH of AVFs or grafts are provided.

Methods and materials for reducing venous neointimal hyperplasia of an arteriovenous fistula or graft

A treatment system includes an insert that is resiliently deflectable. The tip portion of the insert can be configured to be coupled to the trailing portion of an implant. A guide tube having an internal lumen is configured to permit passage of the tip portion and the body portion of the insert through a guide tube. The guide tube can have a length that is less than that of the insert. Treatment systems include a plurality of inserts, each insert differing from in at least one of length, diameter, and curvature. Treating a patient can include sizing a fistula using an insert.

Delivery and assessment aids for implants

This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4lymphocytes, CD8lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14HLA-DRg monocytes, and/or CD86monocytes per unit volume (e.g., cells per &#x3bc;L or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

This document provides methods and materials related to treating renal cell carcinoma. For example, methods and materials for assessing a cancer patient (e.g., a renal cell carcinoma patient) for tumor or peritumoral tissue containing CD14cells and proceeding with a cancer treatment option (e.g., a renal cell carcinoma treatment option) based on the presence, absence, or level of CD14cells present within the tumor or peritumoral tissue are provided.

Methods and materials for treating renal cell carcinoma

This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of CD14/DRcells (e.g., CD14/DRmonocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that change the ratio of CD14/HLA-DRcells to CD14/HLA-DRcells as well as methods and materials for (a) identifying a mammal as being likely to experience an elevated level of CD14/DRcells (e.g., CD14/DRmonocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that reduce the degree to which the mammal develops CD14/DRcells are provided.

Growing community of inventors

Chatfield, MN, United States of America

Allan B Dietz